Useful Advices
#1 in Business Subscribe Email Print

You are here: Home > Business > Sales Management > Small Companies Really Can Compete - Here's How

Tags

  • plans
  • delivery
  • messages
  • winning major
  • winning major
  • biological product

  • Links

  • Weight Loss: Tips for Dining Out and Keep Control on Your Fat Gain
  • Scheduling of Additional Auto Detailing or Mobile Car Wash Units
  • Home Equity Loan Specifics: Loan Terms, Cash Out Limits & Credit for Second Mortgages
  • Useful Advices - Small Companies Really Can Compete - Here's How

    Extensive research recently completed by the Corporate Transformation Department at Luton University in England, confirms suspicions and beliefs that I have had for some time now.

    In business terms, they claim that these findings represent a revolutionary breakthrough in understanding what makes a successful contract bidder.

    Two key facts tell a worrying story:

    1. 50% of them said it is important for them to win new business in
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    order to fulfil their corporate plan.

    2. And yet four out of five companies interviewed win less than half of the bids they pitch for.

    Conclusion: Most companies are not winning enough new contracts to meet their business objectives.

    Not unnaturally, this would cause some anxious looks around the boardroom table if it were not for another key finding from the report.

    A small improvement in bidding techniques and tactics can lead to
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    a disproportionately large increase in the number of contracts won.

    Not surprisingly, the most effective bid winners prefer to draw a veil over those factors that make them successful but the research has pulled the veil aside and provides a glimpse of the critical success factors in winning major bids.

    The companies answered a detailed questionnaire which focussed on two key areas – how successful they were at winning major bids and w
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    at they regard as the factors that made them most successful at winning the bids. Figures are rounded to the nearest decimal point. The companies in the survey represent a cross section of those British companies that compete in major bids either in the UK market or overseas.

    The participants came from industries as diverse as information technology, construction, engineering, aerospace, media, consultancy and utilities.

    The companies
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    were candid about their success. Some 37 per cent admitted they won less than a quarter of the bids they pitched for. A further 40.1 per cent said they won between a quarter and half of their bids. Only 4.1 per cent of the companies claimed to win more than three-quarters of their bids.

    But for these companies, what constitutes “success” at winning major bids? Among the companies 71 per cent “strongly agreed” that it was to win bids at
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    “acceptable profit margins”, while an almost mirror image of 70.6 per cent “strongly disagreed” that it was to win a bid “at any cost”. Among other possible definitions of success 31 per cent strongly agreed that it was winning sufficient bids to achieve growth targets, and 19.2 per cent winning bids from blue-chip customers.

    There was little disagreement that winning major bids was essential to achieving business plans – 52.8 per cent
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    said it was very important to win bids from new customers and 64.5 per cent from existing customers.

    Given that winning major bids is important for achieving business plans, just what is it that gets a company invited to bid in the first place? The companies were invited to rank a number of different factors on a scale running from “very important” to “not important at all”.

    The top five factors are:

    1. Perceived quality of you
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    products/services (68.5 per cent say very important)

    2. Relationships with existing or potential customers (54.4 per cent)

    3. Position of the company in its market-place (52.2 per cent)

    4. The company’s overall image (47.6 per cent)

    5. Track record in similar projects (46.5 per cent)

    However, as the survey shows, more than three-quarters (77.1 per cent) of companies win less than half the bids they pitch for.

    What do the best quar
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    ter have that the other three-quarters lack?

    A year-long research project undertaken by Mathew O’Connor, one of the co-authors of the report, identified 18 activities which seemed to contribute to success in winning major bids. These activities fall under four main categories – assessing the customer’s perception of products/service value, understanding the customer’s buying centre, contacting customer’s and communicating key messages a
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    out the company and it’s products/services (see below)

    Eighteen Critical Activities in Major Bid Projects:

    Assessing your customer’s perception of product/service value:

    1. Understanding the value/benefits customers expect to gain from your products/services (25.6 per cent)

    2. Understanding the cost of ownership issues that impact customer decisions about your products/services (17.9 per cent)

    Understanding your cus
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    tomer’s buying centre - DMU:

    3. Understanding the business environment in which your customers operate (25 per cent)

    4. Understanding each customer’s mission, objectives and markets (15.1 per cent)

    5. Understanding the decision-making process each customer uses (21.3 per cent)

    6. Understanding the factors the customer considers when purchasing(24.6 per cent)

    7. Understanding the roles played by those in the DMU (24.3 per cent)

    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    8. Understanding your customer’s communication network (9.9 per cent)

    Contacting customers:

    9. Maintaining continuing visibility with customers through advertising,mail shots, etc (11 per cent)

    10. Developing person-person relationships with potential customers (44.8 per cent)

    Communicating key messages about your company and product/services:

    11. Communicating key marketplace issues to customers (8.2 per cent)

    12. Co
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    municating generic benefits offered by your products (8.6 per cent)

    13. Establishing the superiority of your products/services (18.1 per cent)

    14. Building a distinctive and helpful image of your company (26.6 per cent)

    15. Establishing an understanding of your market standing (20 per cent)

    16. Communicating the value/benefits of your product/services (20.5 per cent)

    17. Persuading potential customers to invite you to bid (34.1 per
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    cent)

    18. Ability to offer support or ancillary services (23.1 per cent)

    In the survey each of the companies was asked to rank its performance on each of these 18 activities on a five point scale from “very effective” to “not effective at all”.

    The research demonstrates a clear correlation between being effective at these activities and winning a higher proportion of major bids.

    Companies that win less than a quarter of bids claim to
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    perform an average of 2.9 of the activities very effectively. Among companies winning a quarter to half of bids, the number of very effective activities rises to 3.5; those who win half to three quarters of their bids perform 4.9 activities very effectively: among those companies winning more than three-quarters of major bids, the number of very effective activities climbs to 8.7.

    What is perhaps surprising here is that even the most su
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    ccessful companies are accomplishing less than half of the critical 18 activities “very effectively”. It seems pretty clear that those companies prepared to focus on these activities and generate even a modest increase in the number of activities performed very effectively could reap significant improvements in the number of major bids they win.

    Aside from these critical activities, the research has uncovered some important issues for m
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    naging effective bid teams. The companies in the survey were asked to rate 15 aspects of managing bid teams on a five-point scale from “very important” to “not important at all”.

    The top five issues are:

    1. Leadership from senior departmental managers (very important for 64.3 per cent)

    2. Creating a team spirit (55.8 per cent)

    3. Leadership from board of directors (49.5 per cent)

    4. Including team members with specialised kno
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    wledge of the product (46.6 per cent)

    5. Giving clear instructions to team members on how to handle the bid (46.3 per cent)

    Once a pitch is under way there is a fresh range of issues to consider in order to win the bid. The survey companies were asked to rank 11 issues on the same five –point scale.

    The top five issues for completing successful bid negotiations are:

    1. Guaranteeing quality, delivery dates and after sales servi
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    e,etc (very important for 59.9 per cent of companies)

    2. Having a clear bottom line (56.7 per cent)

    3. Developing clear objectives for the negotiations (54.7 per cent)

    4. Preparing detailed bid documentation (48.8 per cent)

    5. Making the first formal presentation of the bid (48.1 per cent)

    Summary:

    There is wide range of different issues that companies need to address more effectively if they are to win more of the bids they
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    pitch for. Bidding relationships with the client is given a particularly high priority in the service sector.There are wide variations in the effectiveness of major bid management between organisations. With more companies increasingly finding themselves pitching against overseas competitors for business, the need to create more effective bid management is more urgent than ever”.

    Copyright © 2006 Jonathan Farrington. All rights reserve


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.usefuladvices.org.ua/article/38550/usefuladvices-Small-Companies-Really-Can-Compete--Heres-How.html">Small Companies Really Can Compete - Here's How</a>

    BB link (for phorums):
    [url=http://www.usefuladvices.org.ua/article/38550/usefuladvices-Small-Companies-Really-Can-Compete--Heres-How.html]Small Companies Really Can Compete - Here's How[/url]

    Related Articles:

    New Year's Sales & Marketing Resolutions

    Business Plans - Beliefs About Business Plans

    Simple School Fundraising ideas

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com